Intravenous magnesium sulfate dilution in normal saline (0.9%)
Intravenous magnesium sulfate infusion for eclampsia/severe preeclampsia is typically prepared by diluting a loading dose (4–6 g) in 0.9% sodium chloride and then continuing with a maintenance infusion at 1–2 g/hour. [1]
Pediatric magnesium sulfate dilution and infusion volume in 0.9% sodium chloride should be weight-based, with infusion over ~20 minutes for acute indications using a maximum dose. [2]
Adult dilution concentration and infusion rate (eclampsia/severe preeclampsia)
Loading dose preparation (0.9% sodium chloride)
- Magnesium sulfate 4–6 g should be diluted in 100 mL of 0.9% normal saline and administered intravenously over 15–20 minutes. [1]
Maintenance infusion concentration and rate
- A premixed maintenance bag should be prepared with magnesium sulfate 20 g per 500 mL (0.9% sodium chloride carrier), which corresponds to 1 g/hour when infused at 250 mL/hour. [3]
- A maintenance infusion of magnesium sulfate 1–2 g/hour should be used with continuous IV infusion. [1]
Pediatric dilution concentration and infusion rate (acute IV use)
Weight-based dilution in 0.9% sodium chloride
- For pediatric IV magnesium sulfate dosing in acute treatment protocols, magnesium sulfate should be diluted in 0.9% sodium chloride to an infusion volume of 5 mL/kg in children weighing <20 kg. [2]
- For pediatric patients weighing ≥20 kg, magnesium sulfate should be diluted in 0.9% sodium chloride to an infusion volume of 100 mL. [2]
Infusion duration and maximum dose
- The pediatric IV infusion should be administered over 20 minutes using an infusion or syringe pump. [2]
- The pediatric magnesium sulfate dose should be 40 mg/kg with a maximum dose of 2 g. [2]
Monitoring for IV magnesium sulfate toxicity and safety
Monitoring during adult maintenance and pediatric infusion
- A complete pre-initiation assessment should include vital signs (including respiratory rate and blood pressure), deep tendon reflexes, and urine output. [3]
Respiratory and neuromuscular monitoring
- Respiratory status should be monitored with attention to respiratory depression as a key toxicity. [3]
- Deep tendon reflexes should be monitored as a key toxicity marker during therapy. [3]
Urine output monitoring
- Urine output should be monitored for adequate renal elimination and to support ongoing dosing safety. [3]
Frequency of clinical monitoring (high-acuity setting)
- During the first hour of magnesium sulfate therapy in acute care protocols, blood pressure, respiratory rate, heart status, and deep tendon reflexes should be assessed every 15 minutes. [2]
Important preparation and administration considerations
- An exclusive IV line should be used for magnesium sulfate to prevent inadvertent incompatibility or dosing errors. [4]
- A calcium antidote should be kept available at the bedside for magnesium toxicity management. [4]
Common stopping criteria and dose interruption triggers
- Magnesium sulfate infusion should be discontinued and serum magnesium checked immediately if deep tendon reflexes are lost, respiratory rate decreases to <12 breaths/minute, or urine output decreases to <30 mL/hour. [1]
Patient-specific adjustment considerations (renal impairment)
- Dose reduction should be used in renal insufficiency because magnesium clearance is decreased and toxicity risk increases. [5]